Motley Fool Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $643K | Buy |
2,978
+59
| +2% | +$11.3K | 0.02% | 174 |
|
|
2026
Q1 | $535K | Buy |
2,919
+378
| +15% | +$69.7K | 0.02% | 173 |
|
|
2025
Q4 | $447K | Buy |
2,541
+153
| +6% | +$25K | 0.02% | 191 |
|
|
2025
Q3 | $335K | Sell |
2,388
-5,109
| -68% | -$691K | 0.01% | 203 |
|
|
2025
Q2 | $942K | Buy |
7,497
+688
| +10% | +$85.7K | 0.04% | 161 |
|
|
2025
Q1 | $932K | Buy |
6,809
+2,676
| +65% | +$383K | 0.05% | 162 |
|
|
2024
Q4 | $632K | Sell |
4,133
-1,728
| -29% | -$291K | 0.03% | 164 |
|
|
2024
Q3 | $1.12M | Buy |
5,861
+204
| +4% | +$42.7K | 0.07% | 153 |
|
|
2024
Q2 | $1.31M | Buy |
5,657
+1,368
| +32% | +$297K | 0.09% | 148 |
|
|
2024
Q1 | $925K | Buy |
4,289
+320
| +8% | +$74.9K | 0.06% | 163 |
|
|
2023
Q4 | $1.03M | Sell |
3,969
-23
| -0.6% | -$5.65K | 0.08% | 152 |
|
|
2023
Q3 | $1.03M | Buy |
3,992
+338
| +9% | +$90.4K | 0.08% | 143 |
|
|
2023
Q2 | $1.04M | Buy |
+3,654
| New | +$1.09M | 0.09% | 136 |
|
|
2023
Q1 | – | Sell |
-3,607
| Closed | -$999K | – | 120 |
|
|
2022
Q4 | $999K | Sell |
3,607
-160
| -4% | -$45.2K | 0.11% | 130 |
|
|
2022
Q3 | $1.01M | Sell |
3,767
-25
| -0.7% | -$5.31K | 0.1% | 131 |
|
|
2022
Q2 | $806K | Sell |
3,792
-140
| -4% | -$28.6K | 0.08% | 149 |
|
|
2022
Q1 | $828K | Buy |
3,932
+123
| +3% | +$26.7K | 0.06% | 155 |
|
|
2021
Q4 | $914K | Sell |
3,809
-65
| -2% | -$16.7K | 0.06% | 155 |
|
|
2021
Q3 | $1.1M | Sell |
3,874
-255
| -6% | -$83.6K | 0.07% | 143 |
|
|
2021
Q2 | $1.43M | Buy |
4,129
+892
| +28% | +$270K | 0.09% | 124 |
|
|
2021
Q1 | $906K | Sell |
3,237
-405
| -11% | -$109K | 0.07% | 140 |
|
|
2020
Q4 | $892K | Buy |
3,642
+272
| +8% | +$70.2K | 0.07% | 138 |
|
|
2020
Q3 | $962K | Buy |
3,370
+238
| +8% | +$66.4K | 0.09% | 118 |
|
|
2020
Q2 | $838K | Buy |
3,132
+120
| +4% | +$36.1K | 0.08% | 115 |
|
|
2020
Q1 | $953K | Sell |
3,012
-186
| -6% | -$56.4K | 0.12% | 106 |
|
|
2019
Q4 | $949K | Sell |
3,198
-80
| -2% | -$22.2K | 0.1% | 107 |
|
|
2019
Q3 | $763K | Sell |
3,278
-27
| -0.8% | -$6.29K | 0.09% | 117 |
|
|
2019
Q2 | $773K | Buy |
3,305
+186
| +6% | +$42.9K | 0.09% | 120 |
|
|
2019
Q1 | $737K | Buy |
3,119
+605
| +24% | +$191K | 0.09% | 115 |
|
|
2018
Q4 | $757K | Sell |
2,514
-96
| -4% | -$30.6K | 0.11% | 107 |
|
|
2018
Q3 | $922K | Buy |
2,610
+396
| +18% | +$136K | 0.11% | 91 |
|
|
2018
Q2 | $643K | Buy |
2,214
+240
| +12% | +$67.5K | 0.09% | 98 |
|
|
2018
Q1 | $541K | Buy |
+1,974
| New | +$613K | 0.08% | 96 |
|
Other funds holding BIIB
Motley Fool Asset Management's BIIB Position: Q2 2026 in Review
Motley Fool Asset Management increased its Biogen (BIIB) stake by 2% in Q2 2026, buying an estimated $11.3K and bringing the position to 2,978 shares worth $643K. The position accounts for 0.02% of the portfolio, ranked #174.
Motley Fool Asset Management first reported a position in BIIB in Q1 2018 and has held it in 33 quarters since. The position peaked at $1.43M in Q2 2021. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Motley Fool Asset Management held 2,978 shares of Biogen worth $643K as of Q2 2026.
- Motley Fool Asset Management bought 59 Biogen shares in Q2 2026, an estimated $11.3K.
- Biogen made up 0.02% of Motley Fool Asset Management's portfolio in Q2 2026, its #174 holding.
- Motley Fool Asset Management first reported a position in Biogen in Q1 2018 and has held it in 33 quarters since.
- Motley Fool Asset Management's Biogen position peaked at $1.43M in Q2 2021.
- 1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Motley Fool Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.